From HAE Poland:

We can proudly announce that the first preventative therapy has been approved and reimbursed in Poland. This is a great and unprecedented achievement of the entire Polish HAE community, a patient organization, and expert physicians, who, together with Takeda, for over 18 months have undertaken various activities to raise awareness of the need to reimburse long-term prophylaxis. Eventually, the Minister of Health approved access to and reimbursement for lanadelumab (Takhzyro) for a group of approximately 50 patients. The approval will be valid until 1 September 2023, and we hope it will be extended thereafter. The HAE community also managed to extend reimbursement indications for icatibant (Firazyr) for the pediatric population. This means that patients under the age of 18 from now on would be able to treat their attacks with this therapeutic option. HAE Poland continues to work intensively to guarantee patients access to another treatment option, recombinant C1-INH (Ruconest).

There are now five ACARE Centers in Poland. The most recent addition to the list is the Department of Internal Diseases at the University Hospital in Opole and the Department of Immunology and Allergy and Department of Psychodermatology at the Central Teaching Hospital under the Medical University of Lodz. For contact information, please see the country page for Poland.